Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 142

1.

Hepatobiliary cancers, version 2.2014.

Benson AB 3rd, D'Angelica MI, Abrams TA, Are C, Bloomston PM, Chang DT, Clary BM, Covey AM, Ensminger WD, Iyer R, Kelley RK, Linehan D, Malafa MP, Meranze SG, Park JO, Pawlik T, Posey JA, Scaife C, Schefter T, Sigurdson ER, Tian GG, Vauthey JN, Venook AP, Yen Y, Zhu AX, Hoffmann KG, McMillian NR, Sundar H.

J Natl Compr Canc Netw. 2014 Aug;12(8):1152-82.

PMID:
25099447
2.

Low dose rate radiosensitization of hepatocellular carcinoma in vitro and in patients.

Cuneo KC, Davis MA, Feng MU, Novelli PM, Ensminger WD, Lawrence TS.

Transl Oncol. 2014 Aug;7(4):472-8. doi: 10.1016/j.tranon.2014.05.006. Epub 2014 Jun 21.

3.

Targeting hepatic cancer cells with pegylated dendrimers displaying N-acetylgalactosamine and SP94 peptide ligands.

Medina SH, Tiruchinapally G, Chevliakov MV, Durmaz YY, Stender RN, Ensminger WD, Shewach DS, Elsayed ME.

Adv Healthc Mater. 2013 Oct;2(10):1337-50. doi: 10.1002/adhm.201200406. Epub 2013 Apr 3.

PMID:
23554387
4.

Dosimetric analysis of radiation-induced gastric bleeding.

Feng M, Normolle D, Pan CC, Dawson LA, Amarnath S, Ensminger WD, Lawrence TS, Ten Haken RK.

Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):e1-6. doi: 10.1016/j.ijrobp.2012.02.029. Epub 2012 Apr 27.

5.

N-acetylgalactosamine-functionalized dendrimers as hepatic cancer cell-targeted carriers.

Medina SH, Tekumalla V, Chevliakov MV, Shewach DS, Ensminger WD, El-Sayed ME.

Biomaterials. 2011 Jun;32(17):4118-29. doi: 10.1016/j.biomaterials.2010.11.068. Epub 2011 Mar 22.

6.

From the guest editors: introduction to local therapies in the treatment of liver cancer.

Ensminger WD, Chang AE.

Cancer J. 2010 Mar-Apr;16(2):91-2. doi: 10.1097/PPO.0b013e3181da5321. No abstract available.

PMID:
20404604
7.

NCCN clinical practice guidelines in oncology: hepatobiliary cancers.

Benson AB 3rd, Abrams TA, Ben-Josef E, Bloomston PM, Botha JF, Clary BM, Covey A, Curley SA, D'Angelica MI, Davila R, Ensminger WD, Gibbs JF, Laheru D, Malafa MP, Marrero J, Meranze SG, Mulvihill SJ, Park JO, Posey JA, Sachdev J, Salem R, Sigurdson ER, Sofocleous C, Vauthey JN, Venook AP, Goff LW, Yen Y, Zhu AX.

J Natl Compr Canc Netw. 2009 Apr;7(4):350-91. No abstract available.

8.

Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition.

Dang DT, Chun SY, Burkitt K, Abe M, Chen S, Havre P, Mabjeesh NJ, Heath EI, Vogelzang NJ, Cruz-Correa M, Blayney DW, Ensminger WD, St Croix B, Dang NH, Dang LH.

Cancer Res. 2008 Mar 15;68(6):1872-80. doi: 10.1158/0008-5472.CAN-07-1589.

9.

Hepatobiliary cancers. Clinical practice guidelines in oncology.

Benson AB 3rd, Bekaii-Saab T, Ben-Josef E, Blumgart L, Clary BM, Curley SA, Davila R, Earle CC, Ensminger WD, Gibbs JF, Laheru D, Langnas AN, Mulvihill SJ, Nemcek AA Jr, Posey JA, Sigurdson ER, Sinanan M, Vauthey JN, Venook AP, Wagman LD, Yeatman TJ; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2006 Sep;4(8):728-50. No abstract available.

PMID:
16948952
10.

Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies.

Ben-Josef E, Normolle D, Ensminger WD, Walker S, Tatro D, Ten Haken RK, Knol J, Dawson LA, Pan C, Lawrence TS.

J Clin Oncol. 2005 Dec 1;23(34):8739-47.

PMID:
16314634
11.

A role for hepatic-directed chemotherapy in colorectal liver metastases.

Ensminger WD.

J Clin Oncol. 2005 Aug 1;23(22):4815-7. Epub 2005 Jul 11. No abstract available.

PMID:
16009957
12.

Disposition of WR-1065 in the liver of tumor-bearing rats following regional vs systemic administration of amifostine.

Levi M, DeRemer SJ, Dou C, Ensminger WD, Smith DE.

Biopharm Drug Dispos. 2004 Jan;25(1):27-35.

13.
14.

Regional delivery and selective expression of a high-activity yeast cytosine deaminase in an intrahepatic colon cancer model.

Zhang M, Li S, Nyati MK, DeRemer S, Parsels J, Rehemtulla A, Ensminger WD, Lawrence TS.

Cancer Res. 2003 Feb 1;63(3):658-63.

15.

Regional pharmacokinetics of amifostine in anesthetized dogs: role of the liver, gastrointestinal tract, lungs, and kidneys.

Levi M, Knol JA, Ensminger WD, DeRemer SJ, Dou C, Lunte SM, Bonner HS, Shaw LM, Smith DE.

Drug Metab Dispos. 2002 Dec;30(12):1425-30.

16.

Intrahepatic arterial infusion of chemotherapy: pharmacologic principles.

Ensminger WD.

Semin Oncol. 2002 Apr;29(2):119-25. Review.

PMID:
11951209
17.

Selective radioprotection of hepatocytes by systemic and portal vein infusions of amifostine in a rat liver tumor model.

Symon Z, Levi M, Ensminger WD, Smith DE, Lawrence TS.

Int J Radiat Oncol Biol Phys. 2001 Jun 1;50(2):473-8.

PMID:
11380236
18.

Interaction between gemcitabine and mitomycin-C in vitro.

Aung TT, Davis MA, Ensminger WD, Lawrence TS.

Cancer Chemother Pharmacol. 2000;45(1):38-42.

19.

Treatment of intrahepatic cancers with radiation doses based on a normal tissue complication probability model.

McGinn CJ, Ten Haken RK, Ensminger WD, Walker S, Wang S, Lawrence TS.

J Clin Oncol. 1998 Jun;16(6):2246-52.

PMID:
9626227
20.

Regional pharmacokinetics of 5-fluorouracil in dogs: role of the liver, gastrointestinal tract, and lungs.

Kuan HY, Smith DE, Ensminger WD, Knol JA, DeRemer SJ, Yang Z, Stetson PL.

Cancer Res. 1998 Apr 15;58(8):1688-94.

21.

A phase I trial of hepatic arterial bromodeoxyuridine and conformal radiation therapy for patients with primary hepatobiliary cancers or colorectal liver metastases.

Robertson JM, McGinn CJ, Walker S, Marx MV, Kessler ML, Ensminger WD, Lawrence TS.

Int J Radiat Oncol Biol Phys. 1997 Dec 1;39(5):1087-92.

PMID:
9392548
22.

A phase I trial of intravenous bromodeoxyuridine and radiation therapy for pancreatic cancer.

Robertson JM, Ensminger WD, Walker S, Lawrence TS.

Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):331-5.

PMID:
9069304
23.

Long-term results of hepatic artery fluorodeoxyuridine and conformal radiation therapy for primary hepatobiliary cancers.

Robertson JM, Lawrence TS, Andrews JC, Walker S, Kessler ML, Ensminger WD.

Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):325-30.

PMID:
9069303
24.
25.

New sources for accessing and interpreting electronic information.

Wolf FM, Miller JG, Ensminger WD.

Acad Med. 1996 May;71(5):524. No abstract available.

PMID:
10676255
26.

Effect of irradiation on bromodeoxyuridine incorporation in human colon cancer xenografts.

Lawrence TS, Chang EY, Davis MA, Stetson PL, Ensminger WD.

Int J Radiat Oncol Biol Phys. 1996 Feb 1;34(3):617-21.

PMID:
8621286
27.

Pelvic radiation therapy combined with hepatic artery chemotherapy for resected rectal carcinoma with liver metastases.

Robertson JM, Cha C, Andrews JC, Ensminger WD, Lawrence TS.

Int J Radiat Oncol Biol Phys. 1996 Jan 1;34(1):155-9.

PMID:
12118545
28.

Incorporation of 5-bromo-2'-deoxyuridine into colorectal liver metastases and liver in patients receiving a 7-day hepatic arterial infusion.

Knol JA, Walker SC, Robertson JM, Yang Z, DeRemer S, Stetson PL, Ensminger WD, Lawrence TS.

Cancer Res. 1995 Sep 1;55(17):3687-91.

29.

The treatment of colorectal liver metastases with conformal radiation therapy and regional chemotherapy.

Robertson JM, Lawrence TS, Walker S, Kessler ML, Andrews JC, Ensminger WD.

Int J Radiat Oncol Biol Phys. 1995 May 15;32(2):445-50.

PMID:
7751185
30.

Hepatic toxicity resulting from cancer treatment.

Lawrence TS, Robertson JM, Anscher MS, Jirtle RL, Ensminger WD, Fajardo LF.

Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1237-48. Review.

PMID:
7713785
31.

Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up.

Andrews JC, Walker SC, Ackermann RJ, Cotton LA, Ensminger WD, Shapiro B.

J Nucl Med. 1994 Oct;35(10):1637-44.

32.

Radiosensitization with carotid intra-arterial bromodeoxyuridine +/- 5-fluorouracil biomodulation for malignant gliomas.

Greenberg HS, Chandler WF, Ensminger WD, Sandler H, Junck L, Page MA, Crane D, McKeever P, Tankanow R, Bromberg J.

Neurology. 1994 Sep;44(9):1715-20.

PMID:
7936303
33.

Kinetics of bromodeoxyuridine elimination from human colon cancer cells in vitro and in vivo.

Lawrence TS, Davis MA, Stetson PL, Maybaum J, Ensminger WD.

Cancer Res. 1994 Jun 1;54(11):2964-8.

34.

Clinical pharmacology of hepatic arterial infusions of 5-bromo-2'-deoxyuridine.

Ensminger WD, Walker SC, Stetson PL, Wagner JG, Knol JA, Lawrence TS, Andrews JC.

Cancer Res. 1994 Apr 15;54(8):2121-4.

35.

Treatment of primary hepatobiliary cancers with conformal radiation therapy and regional chemotherapy.

Robertson JM, Lawrence TS, Dworzanin LM, Andrews JC, Walker S, Kessler ML, DuRoss DJ, Ensminger WD.

J Clin Oncol. 1993 Jul;11(7):1286-93.

PMID:
8391066
36.

Hepatic parenchymal changes after intraarterial Y-90 therapy: CT findings.

Marn CS, Andrews JC, Francis IR, Hollett MD, Walker SC, Ensminger WD.

Radiology. 1993 Apr;187(1):125-8.

PMID:
8451398
37.

Mutual kinetic interaction between 5-fluorouracil and bromodeoxyuridine or iododeoxyuridine in dogs.

Smith DE, Brenner DE, Knutsen CA, Deremer SJ, Terrio PA, Johnson NJ, Stetson PL, Ensminger WD.

Drug Metab Dispos. 1993 Mar-Apr;21(2):277-83.

PMID:
8097697
38.

Regional chemotherapy.

Ensminger WD.

Semin Oncol. 1993 Feb;20(1):3-11. Review. No abstract available.

PMID:
8475407
39.

The potential superiority of bromodeoxyuridine to iododeoxyuridine as a radiation sensitizer in the treatment of colorectal cancer.

Lawrence TS, Davis MA, Maybaum J, Mukhopadhyay SK, Stetson PL, Normolle DP, McKeever PE, Ensminger WD.

Cancer Res. 1992 Jul 1;52(13):3698-704.

40.

Three-dimensional tumor dosimetry for hepatic yttrium-90-microsphere therapy.

Roberson PL, Ten Haken RK, McShan DL, McKeever PE, Ensminger WD.

J Nucl Med. 1992 May;33(5):735-8.

41.

Decrease in TTP pools mediated by 5-bromo-2'-deoxyuridine exposure in a human glioblastoma cell line.

Shewach DS, Ellero J, Mancini WR, Ensminger WD.

Biochem Pharmacol. 1992 Apr 1;43(7):1579-85.

42.

Modulation of iododeoxyuridine-mediated radiosensitization by 5-fluorouracil in human colon cancer cells.

Lawrence TS, Davis MA, Maybaum J, Stetson PL, Ensminger WD.

Int J Radiat Oncol Biol Phys. 1992;22(3):499-503.

PMID:
1735687
43.

The use of 3-D dose volume analysis to predict radiation hepatitis.

Lawrence TS, Ten Haken RK, Kessler ML, Robertson JM, Lyman JT, Lavigne ML, Brown MB, DuRoss DJ, Andrews JC, Ensminger WD, et al.

Int J Radiat Oncol Biol Phys. 1992;23(4):781-8.

PMID:
1618671
44.

Biochemical modulation of 5-bromo-2'-deoxyuridine and 5-iodo-2'-deoxyuridine incorporation into DNA in VX2 tumor-bearing rabbits.

Stetson PL, Normolle DP, Knol JA, Johnson NJ, Yang ZM, Sakmar E, Prieskorn D, Terrio P, Knutsen CA, Ensminger WD.

J Natl Cancer Inst. 1991 Nov 20;83(22):1659-67.

PMID:
1836238
45.

Fluorodeoxyuridine-mediated modulation of iododeoxyuridine incorporation and radiosensitization in human colon cancer cells in vitro and in vivo.

Lawrence TS, Davis MA, McKeever PE, Maybaum J, Stetson PL, Normolle DP, Ensminger WD.

Cancer Res. 1991 Aug 1;51(15):3900-5.

46.

Divergent patterns of incorporation of bromodeoxyuridine and iododeoxyuridine in human colorectal tumor cell lines.

Maybaum J, Burton EC, Shelton DA, Jing HW, Dusenbury CE, Ensminger WD, Stetson PL.

Biochem Pharmacol. 1991 Jun 21;42(1):131-7.

47.

Hepatobiliary toxicity of 5-fluoro-2'-deoxyuridine. Intra-arterial versus portal venous routes of infusion.

Andrews JC, Kuntsen C, Terio P, Priescorn D, Ensminger WD.

Invest Radiol. 1991 May;26(5):461-4.

PMID:
1829068
48.

Treatment of cancers involving the liver and porta hepatis with external beam irradiation and intraarterial hepatic fluorodeoxyuridine.

Lawrence TS, Dworzanin LM, Walker-Andrews SC, Andrews JC, Ten Haken RK, Wollner IS, Lichter AS, Ensminger WD.

Int J Radiat Oncol Biol Phys. 1991 Mar;20(3):555-61.

PMID:
1847363
49.

Variability of 5-bromo-2'-deoxyuridine incorporation into DNA of human glioma cell lines and modulation with fluoropyrimidines.

Mancini WR, Stetson PL, Lawrence TS, Wagner JG, Greenberg HS, Ensminger WD.

Cancer Res. 1991 Feb 1;51(3):870-4.

50.

Microscopic analysis of arterial microsphere distribution in rabbit liver and hepatic VX2 tumor.

Pillai KM, McKeever PE, Knutsen CA, Terrio PA, Prieskorn DM, Ensminger WD.

Sel Cancer Ther. 1991 Summer;7(2):39-48.

PMID:
1754728

Supplemental Content

Loading ...
Support Center